HOME >> BIOLOGY >> NEWS
Blocking a premature aging syndrome with anticancer drugs

A class of anticancer drugs currently being evaluated in phase 3 clinical trials may also be an effective treatment for Hutchinson-Gilford progeria syndrome (HGPS), a fatal genetic disorder that causes premature aging. If upcoming studies in a HGPS mouse model validate the results of experiments in cultured cells in the laboratory, a clinical trial of these drugs in HGPS children may begin as early as next spring.

Brian Capell, a New York University medical student participating in the Howard Hughes Medical Institute/National Institutes of Health Research Scholars Program and the first author of the study, reported the findings in the August 29, 2005, issue of the Proceedings of the National Academy of Sciences. The HHMI-NIH Research Scholars Program gives outstanding medical and dental students the opportunity to conduct biomedical research under the direct mentorship of senior NIH research scientists.

Although HGPS is a rare disease that affects only one child in 4 million, the disease has received wide publicity due to its striking nature. Children born with HGPS appear normal, but they experience growth retardation and show symptoms of accelerated aging -- namely hair loss, skin wrinkling, and fat loss -- around the first year of age. Accelerated cardiovascular disease also ensues, which typically causes death around age 12.

In 2003, researchers in Francis Collins's lab at the National Human Genome Research Institute discovered that mutations in the lamin A (LMNA) gene cause HGPS. The discovery has prompted renewed interest among researchers to study this rare syndrome.

When Capell entered Collins's lab in July 2004, he immediately set his sights on understanding the molecular basis of HGPS. "What really interested me in this research in the first place were the potential links to aging and atherosclerotic disease," says Capell. Indeed, understanding HGPS at the molecular level may illuminate general processes
'"/>

Contact: Jennifer Donovan
donovanj@hhmi.org
301-215-8859
Howard Hughes Medical Institute
29-Aug-2005


Page: 1 2 3

Related biology news :

1. Blocking beta1-integrin to treat cancer
2. Blocking blood vessels provides new option for large group of advanced lung cancer patients
3. Blocking COX-1 slows tumor growth in mice
4. Blocking PLK-1 to beat bladder cancer
5. Blocking neurodegeneration by radiation and bone marrow transfer prevents inherited glaucoma in mice
6. Blocking cell signaling can stymie viral infections, study shows
7. Blocking cell suicide switch fails to stop prion damage in mouse brains
8. Promising protein may prevent eye damage in premature babies
9. Study assesses lung treatments for premature babies
10. Different approach needed to protect brains of premature infants
11. Improving outcomes in premature births

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board ... Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced ... for membership in ARCS Alumni Hall of Fame . ASTER Labs is ...
(Date:10/11/2017)... ... 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. ... San Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, ... government officials from around the world to address key issues in device compliance, quality ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
Breaking Biology Technology:
Cached News: